Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R-PMDT in Newly Diagnosed Primary Central Nervous System Lymphoma
NCT07604987Phase 2Recruiting
- Start
- May 2026
- Primary completion
- May 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pirtobrutinib in primary central nervous system lymphoma (PCNSL). Started May 2026; status: recruiting.
02
Drugs
pirtobrutinib
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on NCT07604987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07604987.